TRADING UPDATES: Galantas Gold buys Andacollo Oro gold project
7th Jan 2026 20:37
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices firm - Tissue Regenix says it is in discussion with its major shareholders and has clear indications of support to raise GBP5 million by way of a convertible loan note. Any fundraise will be subject to shareholder approval. Says a review of its financial position shows that the company has a substantial backlog of creditors, and very limited cash balances. Tissue Regenix says it has an "urgent need" to raise capital by the end of November," adding "without additional funding the company will not be able to continue to trade." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Tissue Regenix PLC on Thursday saw its shares edge lower as it reported a restatement of earnings for financial 2024 and the first half of financial 2025 from a profit to a loss, pairing this with several board changes. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London edged higher at midday in London, shaking off early losses and the threat of a US government shutdown, as investors digested a broad slate of earnings releases. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - Stock prices in London opened lower on Tuesday morning amid a swathe of earnings before a deadline on the last day of the third quarter. Read More
(Alliance News) - Tissue Regenix Group PLC on Monday said sales fell in the first half of 2025 as orders dropped amid economic uncertainty. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and late last week and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - Tissue Regenix Group PLC on Wednesday reported a narrower annual loss and record adjusted earnings, as it looks to future growth despite headwinds in parts of the US market. Read More
(Alliance News) - Tissue Regenix Group PLC on Monday said it has received CE and UK Conformity Assessed certification for OrthoPure XT, its biological tendon replacement technology. Read More
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says European Patent Office grants European patent (EP4114476) for its decellularisation technology, dCELL. The patent relates to the method for producing decellularisation tissue scaffold which is a foundation for Tissue Regenix's platform and plays a pivotal role in the development of its product range. This patent adds to those the company already has granted in the US and UK for dCELL. Read More
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Revenue increases 8% to USD28.4 million in the year ending December 31 from USD26.3 million a year prior. In addition, expects to report an adjusted earnings before interest, tax, depreciation and amortisation above expectations. Notes this will mark the second full year of profitability for Tissue Regenix and the fourth year of above-market growth. Read More
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - In response to press reports, say that it is conducting a review of strategic options, which may include soliciting offers for Tissue Regenix. Accordingly, the firm has contacted a limited number of potential counterparties to assess whether they could put forward a proposal "that would deliver greater value to Tissue Regenix's shareholders than pursuing a standalone independent strategy". Says it has not received any indicative non-binding proposals to date, and says there can be no certainty any offer will be made. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says trading in the first half of 2024 was strong, as it expects revenue to have climbed 16% to USD16.4 million from USD14.1 million a year prior. "The BioRinse segment continued to deliver solid growth driven by increased efficiencies, while the commercial reorganisation of the dCELL segment continued to show benefits, demonstrating robust growth within the period," Tissue Regenix says. It will report its full half-year results on September 10. Read More